UCB SA (OTCMKTS:UCBJF) Sees Significant Increase in Short Interest

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the recipient of a large increase in short interest in May. As of May 15th, there was short interest totalling 373,700 shares, an increase of 49.8% from the April 30th total of 249,500 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 3,737.0 days. Approximately 0.2% of the company's stock are sold short.

UCB Price Performance

UCB stock remained flat at $179.39 during midday trading on Thursday. UCB has a 52-week low of $149.85 and a 52-week high of $209.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The company's 50 day moving average is $163.18 and its two-hundred day moving average is $179.93.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.